• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Engineered Lectin Microarray Accurately Profiles Glycans Directly on Intact Therapeutic Antibodies

by
November 14, 2026
in Health
Reading Time: 6 mins read
0
Engineered Lectin Microarray Accurately Profiles Glycans Directly on Intact Therapeutic Antibodies

Engineered Lectin Microarray Accurately Profiles Glycans Directly on Intact Therapeutic Antibodies

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers have evaluated a novel second-generation lectin microarray platform capable of semi-quantitative glycan profiling directly on intact therapeutic monoclonal antibodies, demonstrating high concordance with conventional mass spectrometry. N-linked glycosylation represents a critical quality attribute of therapeutic monoclonal antibodies that strongly influences clinical efficacy, safety, and pharmacokinetics. As of May 2025, the United States Food and Drug Administration had approved 209 therapeutic antibodies, encompassing 160 innovator products and 49 biosimilars. The vast majority belong to immunoglobulin G subclasses, specifically IgG1 at 73 percent, IgG2 at 8 percent, and IgG4 at 15 percent. Within IgG1 molecules, a conserved N-linked glycosylation site at asparagine 297, or Asn297, in the crystallizable fragment region modulates vital effector functions, including antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. These immunological functions are mediated through interactions with Fc gamma receptors on effector cells and with complement cascade proteins. More than 30 distinct N-glycan species can occupy Asn297, creating extensive microheterogeneity that governs biological activity.

Regulatory guidelines emphasize the necessity of detailed glycan profiling during drug development and manufacturing. The International Council for Harmonisation Q6B guideline recommends evaluating total carbohydrate content, neutral sugars, sialic acids, glycosylation sites, and complete structural features including monosaccharide composition, oligosaccharide sequence, branching, and glycosidic linkages. Analytical comparability assessments are essential to detect glycosylation shifts introduced by cell line selection, culture conditions, bioreactor scale-up, or purification procedures. The standard analytical workflow requires releasing N-glycans from the antibody backbone using peptide-N-glycosidase F, typically through an incubation requiring four hours to overnight after protein denaturation. Cleaved glycans undergo fluorescent tagging with reagents such as 2-aminobenzamide or RapiFluor-MS to ensure sensitive detection. Tagged glycans are subsequently separated by hydrophilic interaction liquid chromatography, identified by mass spectrometry, and quantified through chromatographic peak areas. This multi-step procedure represents the established industry benchmark for monoclonal antibody characterization.

Despite its precision, conventional glycan analysis involves notable operational hurdles. Releasing, labeling, and purifying glycans requires substantial labor and material, consuming up to 15 micrograms of antibody even in rapid digestion protocols. Multi-step sample preparation introduces risks of incomplete enzymatic digestion or loss of scarce glycoforms, distorting relative abundance estimates. Chromatographic separation requires individual sample injections lasting up to an hour, limiting sample throughput. Lectin microarrays provide an orthogonal, high-throughput alternative that analyzes intact glycoproteins directly without chemical or enzymatic glycan release. Preserving the native protein structure and crystallizable fragment conformation, the microarray operates with only one microgram of antibody. The platform uses immobilized carbohydrate-binding lectins that recognize specific glycan epitopes. Evanescent-field fluorescence detection excites only fluorophores bound to immobilized lectins at the chip surface, permitting real-time monitoring of binding interactions without post-incubation washing steps, significantly streamlining experimental execution.

Earlier first-generation lectin microarrays containing 45 distinct lectins demonstrated proof of principle for glycoprotein profiling but suffered from non-specific signals that complicated data analysis. In prior profiling of therapeutic antibodies approved by the Food and Drug Administration, researchers identified nine prevalent glycan epitopes consistently expressed across production systems. These benchmark epitopes comprise core fucose, terminal N-acetylglucosamine, terminal beta-galactose, high mannose, terminal alpha-galactose, terminal alpha-2,3-linked N-acetylneuraminic acid, terminal alpha-2,6-linked N-glycolylneuraminic acid, triantennary architectures, and bisecting N-acetylglucosamine. To capture these epitopes cleanly, researchers engineered the second-generation LecChip-IgG-mAb platform featuring nine tailored lectins printed in triplicate across 14 distinct wells. Because a single glycan structure can display multiple distinct epitopes that engage different lectins, and individual epitopes appear across multiple coexisting glycoforms, the array generates cumulative fluorescence signals reflecting overall epitope presence, establishing an efficient semi-quantitative profiling system.

To rigorously validate the analytical performance and specificity of the LecChip-IgG-mAb, investigators assembled two complementary test sets of monoclonal antibodies. The primary validation cohort consisted of recombinant anti-HER2 antibodies possessing the amino acid sequence of trastuzumab, expressed in human embryonic kidney HEK293T suspension cells. Chemoenzymatic glycoengineering was employed to synthesize eight distinct, homogeneous glycoform variants: Ab-G0, Ab-G0F, Ab-G1F with a 3-arm galactose, Ab-G1F with a 6-arm galactose, Ab-G2, Ab-G2F, Ab-S2G2, and Ab-S2G2F. IdeS protease digestion coupled with liquid chromatography-mass spectrometry verified initial glycoengineering fidelity. The second sample set comprised commercially sourced pharmaceutical adalimumab products, consisting of three lots of the innovator reference medicine Humira with distinct expiration dates alongside single lots of eight approved biosimilars. This dual evaluation framework allowed the team to systematically compare microarray binding responses against chemically defined, homogenous glycostructures while testing platform utility across commercially approved therapeutics sharing close glycosylation similarity.

Mass spectrometry of released glycans provided the definitive benchmark for confirming anti-HER2 glycoform structures. Following filter-aided sample preparation using 30-kilodalton filtration units, 20 micrograms of each antibody was reduced with 10 millimolar dithiothreitol, alkylated with 40 millimolar iodoacetamide in 8 molar urea, and deglycosylated with 1,500 units of PNGase F for 18 hours. Cleaved glycans were enriched on amino columns, reduced with ammonia borane, permethylated using solid-phase sodium hydroxide beads and iodomethane, and analyzed on a Bruker UltrafleXtreme MALDI-TOF mass spectrometer with 2,5-dihydroxybenzoic acid matrix. MALDI-TOF analysis confirmed that four variants—Ab-G0, Ab-G0F, Ab-G2, and Ab-G2F—were completely homogenous, showing exclusively the target glycoform. The Ab-G1F 3-arm and 6-arm preparations contained G1F as the predominant glycan along with 12.2 percent and 0.1 percent residual G0F, respectively. MALDI-TOF spectra revealed partial desialylation in Ab-S2G2 and Ab-S2G2F following transport and storage, leaving 70.4 percent intact S2G2 and 64.4 percent intact S2G2F, while monosialylated species accounted for roughly 30 percent.

Lectin microarray analysis of the intact anti-HER2 antibodies showed high concordance with mass spectrometry data. Intact antibodies labeled with Cy3 dye were diluted to 125 nanograms per milliliter, incubated overnight across microarray wells, and imaged on a GlycoStation Reader 2300. Ab-G0 yielded intense binding to the terminal GlcNAc-specific lectin rOTH3, while Ab-G0F generated strong signals for both terminal GlcNAc and core fucose recognized by rPhoSL. Ab-G2 produced strong fluorescence for terminal beta-galactose on RCA120, and Ab-G2F showed signals for both beta-galactose and core fucose. Both S2G2 and S2G2F variants displayed robust binding to the alpha-2,6-linked sialic acid lectin and moderate binding to beta-galactose, though fucose binding in Ab-S2G2F was partially attenuated by steric hindrance from terminal sialic acids. Lectins targeting high mannose, alpha-2,3-linked sialic acid, terminal alpha-galactose, and triantennary glycans exhibited negligible binding across all eight samples at 1-second exposure, confirming high assay specificity for intact therapeutic antibodies.

Dynamic range and intermediate precision analyses established the quantitative boundaries of the second-generation lectin microarray platform. Using an equimolar mixture of Ab-G0F and Ab-G2F serially diluted from 15.6 to 2,000 nanograms per milliliter, researchers evaluated signal linearity across 1, 2, and 10-second exposure times. At 1-second exposure, fluorescence scaled linearly up to 1,000 nanograms per milliliter for core fucose, terminal GlcNAc, and terminal beta-galactose lectins, maintaining regression coefficients of determination of 0.98 or higher. At 2 seconds, the linear range contracted to 500 nanograms per milliliter for fucose and GlcNAc, and narrowed further to 125 nanograms per milliliter at 10 seconds due to signal saturation and self-quenching. Intermediate precision assessments at 125 nanograms per milliliter yielded inter-day coefficients of variation of 23.6 percent for terminal GlcNAc, 24.9 percent for core fucose, and 35.6 percent for terminal beta-galactose at 1-second exposure. Intra-chip variation ranged from 3.5 to 26.2 percent for GlcNAc, 7.0 to 29.2 percent for fucose, and 11.9 to 29.9 percent for beta-galactose across individual chips.

Applying the LecChip-IgG-mAb platform to pharmaceutical adalimumab products confirmed its suitability for evaluating biosimilar comparability. In all three reference Humira lots and the eight commercial biosimilars, terminal GlcNAc exhibited the highest fluorescence intensity, closely followed by core fucose, with both dominant epitopes cleanly detected at 1-second exposure. Lower-abundance epitopes, including terminal beta-galactose and high mannose, emerged distinctly at 10-second exposure, while trace signals for alpha-2,3-linked sialic acid appeared in several samples, aligning with reported levels of 0.1 to 1.1 percent sialic acid in Chinese hamster ovary cell-derived adalimumab. Statistical acceptance criteria established from 15 reference product replicates (mean plus or minus three standard deviations) successfully encompassed the average epitope intensities for all eight biosimilars as well as the majority of individual replicates. These results demonstrated that the lectin microarray accurately identifies comparable glycan profiles in commercial biotherapeutics known to possess matching glycosylation under traditional release testing methods.

The study also outlined technical limitations and prospective improvements for lectin microarray technology. Because lectins differ in binding affinity, fluorescence signals reflect both epitope abundance and binding strength, making the assay semi-quantitative rather than absolute. The platform cannot resolve positional isomers, such as 3-arm versus 6-arm GlcNAc linkages in G1F structures, a constraint shared by MALDI-TOF mass spectrometry without tandem fragmentation. Deploying the platform for in-process bioreactor monitoring requires prior antibody purification, as Cy3 dye reacts non-specifically with culture amines and media carbohydrates can cause competitive inhibition. Nonetheless, by analyzing up to 14 intact antibody samples per chip without glycan release and resolving critical alpha-2,6 versus alpha-2,3 sialic acid linkages, the second-generation lectin microarray provides a rapid, sample-sparing orthogonal technique supporting biopharmaceutical development.

Subject of Research: High-throughput glycan epitope profiling of intact therapeutic monoclonal antibodies using a second-generation lectin microarray

Article Title: Second-generation lectin microarray for high throughput glycan profiling of therapeutic antibodies

Article References: Hess, K., Yun, H., Luo, S., Ortega-Rodriguez, U., Henry Lunde, G., Rogstad, S., Wang, L.-X., & Zhang, B. (2026). Second-generation lectin microarray for high throughput glycan profiling of therapeutic antibodies. AAPS Open, 12(1), Article 32. https://doi.org/10.1186/s41120-026-00172-4

Image Credits: AI Generated

DOI: 10.1186/s41120-026-00172-4

Keywords: lectin microarray, therapeutic monoclonal antibodies, N-linked glycosylation, glycan profiling, mass spectrometry, MALDI-TOF, trastuzumab, adalimumab, biosimilar characterization, chemoenzymatic glycoengineering, core fucose, terminal GlcNAc, terminal beta-galactose, sialic acid linkages, intermediate precision, dynamic range, LecChip-IgG-mAb, evanescent-field fluorescence

News Source: Ophelia Keating. (November 14, 2026). Engineered Lectin Microarray Accurately Profiles Glycans Directly on Intact Therapeutic Antibodies. Scienmag.

Tags: adalimumabbiosimilar characterizationchemoenzymatic glycoengineeringcore fucosedynamic rangeevanescent-field fluorescenceglycan profilingintermediate precisionLecChip-IgG-mAblectin microarrayMALDI-TOFmass spectrometryN-linked glycosylationsialic acid linkagesterminal beta-galactoseterminal GlcNActherapeutic monoclonal antibodiestrastuzumab
Share12Tweet7Share2ShareShareShare1

Related Posts

Multicenter Study Examines Clinical Outcomes in Keratitis-Associated Endophthalmitis

Multicenter Study Examines Clinical Outcomes in Keratitis-Associated Endophthalmitis

November 19, 2026
Review Synthesizes Direct Conflict Harms and Global Health Supply Disruptions

Review Synthesizes Direct Conflict Harms and Global Health Supply Disruptions

November 19, 2026

Review Outlines How Caveolae and Junction Crosstalk Aggravates Post-Stroke Barrier Injury

November 19, 2026

Positive Identity and Learning Commitment Linked to Reduced Anxiety in Deaf Adolescents

November 19, 2026

POPULAR NEWS

  • First-Principles Calculations Reveal High Thermoelectric Efficiency and Half-Metallicity in Co2VPb Alloy

    First-Principles Calculations Reveal High Thermoelectric Efficiency and Half-Metallicity in Co2VPb Alloy

    29 shares
    Share 12 Tweet 7
  • Mobile Bird Hosts Enable Regional Gene Flow in Crater Lake Parasites

    29 shares
    Share 12 Tweet 7
  • Ultrasound Shows Low Diagnostic Accuracy for Sexing Immature Agile Frogs

    29 shares
    Share 12 Tweet 7
  • Lithuanian Forest Foragers Link Solitary Mushroom Gathering to Cross-Border Trade

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Domestic Ancestry Associated With Shorter Daily Movements, Reduced Migration in Mallards

Multicenter Study Examines Clinical Outcomes in Keratitis-Associated Endophthalmitis

Brain Phase Synchronization Modes Underlie Diverse Social Orienting in Autistic Youths

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.